STRO (Sutro Biopharma) Other Gross PPE: $16.82 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STRO Sutro Biopharma Inc STRO
45 GF Score
Price $20.46
GF Value $5.50
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Sutro Biopharma Other Gross PPE?

Sutro Biopharma STRO -4.16% 45 Other Gross PPE is $16.82 Mil as of Jun. 2026. GuruFocus rates STRO with a GF Score™ of 45/100 and a GF Value™ of $5.50 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Sutro Biopharma's Other Gross PPE for the quarter that ended in Jun. 2026 was $16.82 Mil.

Sutro Biopharma's quarterly Other Gross PPE declined from Dec. 2025 ($47.17 Mil) to Mar. 2026 ($19.07 Mil) and declined from Mar. 2026 ($19.07 Mil) to Jun. 2026 ($16.82 Mil).

Sutro Biopharma's annual Other Gross PPE declined from Dec. 2023 ($84.43 Mil) to Dec. 2024 ($82.13 Mil) and declined from Dec. 2024 ($82.13 Mil) to Dec. 2025 ($47.17 Mil).

Sutro Biopharma Other Gross PPE Historical Data

* Premium members only.

The historical data trend for Sutro Biopharma's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sutro Biopharma Other Gross PPE Chart

Sutro Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Gross PPE
Get a 7-Day Free Trial Premium Member Only Premium Member Only 82.92 85.50 84.43 82.13 47.17

Sutro Biopharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Gross PPE Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 29.82 26.69 47.17 19.07 16.82
STRO
45GF Score
Sutro Biopharma Inc STRO
Other Gross PPE is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sutro Biopharma Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.

Frequently Asked Questions Learn more about Other Gross PPE →
What does a Other Gross PPE of $16.82 Mil mean?
Sutro Biopharma (STRO) has a Other Gross PPE of $16.82 Mil as of Jun. 2026. Other Gross PPE is property, plant and equipment recorded on a company's balance sheet that not otherwise classified. View historical data on Sutro Biopharma and its competitors.
Is Sutro Biopharma's Other Gross PPE too high?
Sutro Biopharma's current Other Gross PPE is $16.82 Mil. Overall, Sutro Biopharma has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sutro Biopharma's Other Gross PPE compare to AVIR and IPSC?
Sutro Biopharma's Other Gross PPE of $16.82 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Gross PPE for a Biotechnology company?
A good Other Gross PPE depends on the Biotechnology industry context. However, Other Gross PPE should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Gross PPE mean?
A high Other Gross PPE can signal that a stock is expensive relative to its fundamentals. Other Gross PPE is property, plant and equipment recorded on a company's balance sheet that not otherwise classified. View historical data on Sutro Biopharma and its competitors. Sutro Biopharma's current Other Gross PPE is $16.82 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sutro Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Sutro Biopharma (STRO) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.50, compared to a current price of $20.46 — trading 272% above its estimated fair value. The current Other Gross PPE is $16.82 Mil. Sutro Biopharma's overall GF Score™ is 45/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Gross PPE calculated?
Other Gross PPE is calculated from a company's financial statements. For Sutro Biopharma (STRO), the current Other Gross PPE is $16.82 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sutro Biopharma (STRO) Overvalued in 2026?

Based on GuruFocus' analysis, Sutro Biopharma stock appears to be overvalued. The current stock price of $20.46 is trading 272% above its estimated GF Value™ of $5.50. GuruFocus considers Sutro Biopharma to be Significantly Overvalued.

Key valuation signals for STRO:

  • Other Gross PPE: $16.82 Mil
  • GF Value™: $5.50 vs. price of $20.46 (272% above fair value)
  • GF Score™: 45/100 with 4 warning signs

No single metric tells the full story. See the STRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sutro Biopharma Business Description

Other Exchanges S090:Germany
Address 111 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
45GF Score

Get the complete analysis for STRO

Other Gross PPE is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$20.46
Price
$5.50
GF Value